Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek Dinart

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Pharmaceutical Statistics|July 17, 2024
Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker-Strategy Designs With Multiple TreatmentsDerek Dinart, Virginie Rondeau, Carine Bellera
Biometrics|July 9, 2021
Sample size estimation for cancer randomized trials in the presence of heterogeneous populationsDerek Dinart, Carine Bellera, Virginie Rondeau
Journal of Biopharmaceutical Statistics|February 9, 2024
Sample size estimation for recurrent event data using multifrailty and multilevel survival modelsDerek Dinart, Carine Bellera, Virginie Rondeau
Statistics in Medicine|June 8, 2026
Empirical Comparison of Win Ratio and Joint Frailty Models for Recurrent Event Endpoints With Applications in Oncology and CardiologyAdrien Orué, Derek Dinart, Laurent Billot, et al.
Current Oncology Reports|March 29, 2025
The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting GuidelinesKilian Trin, Cynthia Dalleau, Simone Mathoulin-Pelissier, et al.
Critical Reviews in Oncology/Hematology|February 28, 2018
Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical reviewMarion Savina, Sophie Gourgou, Antoine Italiano, et al.
The Oncologist|April 25, 2019
Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival AnalysisKevin Bourcier, Derek Dinart, Axel Le Cesne, et al.
Critical Reviews in Oncology/Hematology|November 23, 2024
Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trialsCamille Baudelin, Paul Sargos, Derek Dinart, et al.
Cancers|June 12, 2026
Beyond Surgical Margins: Fully Mature Tertiary Lymphoid Structures (fmTLSs) Are Predictive Biomarkers for Local Recurrence in Primary Soft-Tissue SarcomasAudrey Michot, Lucile Vanhersecke, Derek Dinart, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|July 17, 2024
Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker-Strategy Designs With Multiple TreatmentsDerek Dinart, Virginie Rondeau, Carine Bellera
Biometrics|July 9, 2021
Sample size estimation for cancer randomized trials in the presence of heterogeneous populationsDerek Dinart, Carine Bellera, Virginie Rondeau
Journal of Biopharmaceutical Statistics|February 9, 2024
Sample size estimation for recurrent event data using multifrailty and multilevel survival modelsDerek Dinart, Carine Bellera, Virginie Rondeau
Statistics in Medicine|June 8, 2026
Empirical Comparison of Win Ratio and Joint Frailty Models for Recurrent Event Endpoints With Applications in Oncology and CardiologyAdrien Orué, Derek Dinart, Laurent Billot, et al.
Current Oncology Reports|March 29, 2025
The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting GuidelinesKilian Trin, Cynthia Dalleau, Simone Mathoulin-Pelissier, et al.
Critical Reviews in Oncology/Hematology|February 28, 2018
Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical reviewMarion Savina, Sophie Gourgou, Antoine Italiano, et al.
The Oncologist|April 25, 2019
Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival AnalysisKevin Bourcier, Derek Dinart, Axel Le Cesne, et al.
Critical Reviews in Oncology/Hematology|November 23, 2024
Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trialsCamille Baudelin, Paul Sargos, Derek Dinart, et al.
Cancers|June 12, 2026
Beyond Surgical Margins: Fully Mature Tertiary Lymphoid Structures (fmTLSs) Are Predictive Biomarkers for Local Recurrence in Primary Soft-Tissue SarcomasAudrey Michot, Lucile Vanhersecke, Derek Dinart, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.
Pageof 2